LCLijun Cai

Lijun Cai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lijun Cai has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Bei Zhang

    Department of Ultrasound Medicine, The Affiliated Hospital of Guizhou Medical University, Guiyang, P.R. China

    2 shared publications
  • Bing Han

    Department of Pathophysiology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, China

    2 shared publications
  • Li Zhang

    Department of Neurology, The Affiliated Hospital of Guizhou Medical University, Guiyang, P.R. China

    2 shared publications
  • Rujia Xie

    Department of Pathophysiology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, China

    2 shared publications
  • Shuang Tang

    Department of Pathophysiology, College of Basic Medical Sciences, Guizhou Medical University, Guiyang, China

    2 shared publications
  • Song Deng

    Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, China

    2 shared publications

Latest Publications

  • Open Access

    Targeting microglial inflammation in Parkinson’s disease: irisin activates PAFAH1B1-RAGE ubiquitination and TFEB-dependent autophagy to alleviate neurodegeneration

    by Lijun Cai, Yin Liu, Shuang Tang, Song Deng, Li Zhang, Yiping Wang, Bei Zhang, Bing Han, Rujia Xie, Xin Liao, et al.

    Investigate irisin’s therapeutic potential in Parkinson’s disease (PD). Clinical data from 120 PD patients and 120 controls were analyzed. MPTP-induced PD mice and LPS-stimulated BV2 microglia models were used. In vivo, mice were divided into control, PD, and PD + Irisin groups for behavioral and histological assessments. In vitro, LPS-stimulated BV2 cells were treated with irisin or PBS. RNA sequencing, immunohistochemistry, and Western blot evaluated autophagy, inflammation, and ubiquitination pathways. PD patients exhibited increased TNF-α and IL-1β but decreased irisin levels. In PD mouse models, irisin improved motor deficits, increased nigrostriatal neuron numbers, restored tyrosine hydroxylase expression, and reduced α-synuclein aggregation. It also suppressed microglial inflammation and promoted anti-inflammatory polarization. Mechanistically, irisin enhanced autophagic flux, regulated RAGE ubiquitination mediated by PAFAH1B1, and inhibited neuroinflammation via the TFEB-NLRP3 axis. Specifically, PAFAH1B1 regulated RAGE expression through K61 and K169 sites on K48-linked polyubiquitin chains. Additionally, irisin restored lysosomal function by promoting TFEB nuclear translocation, enhancing NLRP3 inflammasome degradation, and reducing inflammatory factor secretion, thus alleviating neuroinflammation. Irisin alleviates PD pathology by modulating autophagy and ubiquitination pathways, suggesting its potential as a novel immunomodulatory target for PD.


  • Open Access

    Irisin inhibits dopaminergic neuron lactate metabolism and repairs mitochondrial function to alleviate Parkinson’s disease by activating SIRT1 signaling pathway

    by Lijun Cai, Yin Liu, Shuang Tang, Song Deng, Li Zhang, Xin Liao, Bei Zhang, Bing Han, Rujia Xie

    Irisin, an exercise-induced myokine with promising therapeutic potential, exhibits neuroprotective effects in Parkinson’s disease (PD). However, its underlying mechanisms remain poorly understood. This study investigated the role of irisin in an MPTP-induced mouse model of PD. Irisin treatment improved motor function, as evidenced by enhanced performance on the rotarod test, and promoted dopaminergic neuron survival, demonstrated by increased TH-positive cell counts and reduced α-synuclein accumulation. Additionally, irisin inhibited lactate metabolism in the substantia nigra by decreasing lactate and pyruvate levels and downregulating key glycolytic enzymes. Mitochondrial function was restored through reductions in oxidative stress markers and improvements in ATP synthesis and mitochondrial morphology. Furthermore, irisin activated the SIRT1 signaling pathway, leading to the deacetylation of HIF-1α and PGC-1α, which suppressed apoptosis and enhanced cell viability in MPP + -treated SH-SY5Y cells. Irisin also attenuated neuroinflammation by reducing microglial activation and protecting neurons from microglia-induced apoptosis. These findings demonstrate that irisin confers neuroprotection in PD through multiple mechanisms, including the regulation of motor function, dopaminergic neuron survival, mitochondrial function, and neuroinflammation. Activation of the SIRT1 pathway appears to be a core therapeutic target for these effects of irisin.